Importantly, patients who have previously failed ICI therapy should be considered as eligible for CDK4/6i-ICI combination trials, given the capacity for CDK4/6i to directly induce both tumor- and CTL-intrinsic transcriptional signatures associated with favorable ICI responses. Here, CDK4 is linked to neoplasm.